CJC-1295 Ipamorelin FDA Status 2026

CJC-1295 Ipamorelin FDA Status 2026. CJC-1295 Ipamorelin FDA status in 2026: approval, compounding, Category 2 safety concerns, and research-only availability. Key Takeaways CJC-1295 plus Ipamorelin is not FDA approved: There is no approved CJC-1295/Ipamorelin brand, finished drug, or human therapeutic indication. The two peptides have separate FDA concerns: FDA flagged CJC-1295 for limited clinical data and serious adverse events including increased heart rate and systemic vasodilatory reaction; Ipamorelin acetate is listed with immunogenicity, impurity, and limited-route safety concerns. Compounding status is not the same as FDA approval: Even if a clinic or pharmacy markets a blend, that does not make it an FDA-approved medication. CJC-1295 naming is messy: FDA evaluated multiple CJC-1295-related bulk substances because no-DAC, DAC, free-base, acetate, and TFA naming can be inconsistent. Research-only sourcing requires verification: For laboratory use, batch-specific COAs, identity testing, and HPLC purity matter more than clinic marketing language. The short answer for CJC-1295 Ipamorelin FDA status 2026 is simple: the combination is not FDA approved. Neither CJC-1295 nor Ipamorelin has an approved human therapeutic indication, and the combined CJC-1295/Ipamorelin blend has not been approved as a finished drug product. This article separates three questions that often get blurred together: FDA approval, compounding eligibility, and research-only availability. For mechanism and study-design context, start with our CJC-1295 vs Ipamorelin research comparison ; this page focuses on the regulatory status. CJC-1295 Ipamorelin FDA Status at a Glance Question 2026 Answer Why It Matters Is CJC-1295 FDA approved? No FDA states CJC-1295 is not a component of an FDA-approved drug. Is Ipamorelin FDA approved? No Ipamorelin remains a research peptide, not an approved medication. Is the CJC-1295/Ipamorelin blend approved? No Combining two unapproved peptides does not create an approved product. Is compounding the same as approval? No Compounding rules and FDA drug approval are separate pathways. Can it be sold for research? Research-use only Research chemical availability depends on RUO labeling and vendor compliance. FDA Approval vs Compounding vs Research Use Most confusion around CJC-1295 Ipamorelin FDA approval status comes from mixing up three separate categories: FDA approval: A sponsor submits clinical data through an NDA or BLA, and FDA approves a finished drug for a specific indication. Compounding: A pharmacy prepares a medication under 503A or 503B rules. This does not mean the compounded substance is itself FDA approved. Research use only: A chemical supplier sells material for laboratory research with no human-use claims. CJC-1295/Ipamorelin fails the first test: there is no FDA-approved product. The compounding question is narrower and more unsettled because FDA has evaluated or listed related bulk substances due to safety and characterization concerns. What FDA Said About CJC-1295 FDA's Pharmacy Compounding Advisory Committee briefing for CJC-1295-related bulk drug substances reviewed multiple forms: CJC-1295 free base, CJC-1295 acetate, CJC-1295 DAC free base, CJC-1295 DAC acetate, and CJC-1295 DAC TFA. The agency highlighted several issues: No FDA-approved component: FDA noted that none of the evaluated CJC-1295-related substances are components of an FDA-approved drug. Naming confusion: FDA described inconsistent naming around no-DAC, DAC, free-base, and salt forms. Peptide complexity: The briefing emphasized immunogenicity, self-association, aggregation, peptide-related impurities, and characterization challenges. Safety signals: FDA's significant-risk list cites serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reaction. Limited clinical data: FDA described the available clinical data as limited. That is why searches like FDA status CJC-1295 Ipamorelin compounding 2026 need a careful answer. CJC-1295 is not merely "not approved"; FDA has also documented compounding-specific concerns about identity, impurities, and safety. What FDA Said About Ipamorelin Ipamorelin acetate appears in FDA's significant-risk compounding materials. FDA's concerns include potential immunogenicity for certain administration routes, peptide-related impurities, and the fact that Ipamorelin acetate contains unnatural amino acids that add characterization complexity. FDA also cited serious adverse events, including death, in a study where Ipamorelin was administered intravenously for improving gastric motility. FDA stated it lacked safety-related information for certain other injectable routes, meaning the agency did not have enough information to determine whether harm would occur through those routes. For the individual compound, see our Ipamorelin FDA approval status guide. The combination page you are reading applies that same regulatory logic to the CJC-1295/Ipamorelin blend. Why the Combination Is Common Anyway The pairing is popular in research and clinic marketing because CJC-1295 and Ipamorelin target different growth-hormone signaling pathways: Compound Class Primary Pathway FDA Status CJC-1295 GHRH analog GHRH receptor signaling Not approved Ipamorelin GHRP / ghrelin mimetic GHS-R1a signaling Not approved CJC-1295 + Ipamorelin Combination research blend Dual pathway GH secretagogue model Not approved Mechanistic complementarity is not the same as regulatory approval. A combination can be scientifically interesting and still remain unapproved for human use. CJC-1295 DAC vs No DAC Status CJC-1295 naming matters because "CJC-1295" can refer to different molecules. The DAC version uses a drug affinity complex that extends half-life through albumin binding. The no-DAC version is commonly referred to as modified GRF 1-29 in research contexts. FDA's CJC-1295 evaluation explicitly separated CJC-1295 free base from CJC-1295 DAC free base and related salt forms. That matters because a clinic, vendor, or COA may use shorthand naming that hides which active moiety is actually present. How This Compares With Tesamorelin and Sermorelin Researchers often compare CJC-1295/Ipamorelin with older growth-hormone-axis peptides: Tesamorelin: FDA approved as Egrifta for HIV-associated lipodystrophy, making it the clean regulatory comparison point in this class. Sermorelin: Previously approved as Geref but discontinued; still has a different regulatory history than CJC-1295. CJC-1295/Ipamorelin: No approved brand, no approved indication, and compounding-specific safety concerns. For a broader comparison with direct growth hormone use, read our CJC-1295 Ipamorelin vs HGH article. Research-Only Vendor Checklist For laboratory research, the regulatory question becomes a quality-control question. Any CJC-1295/Ipamorelin source should be evaluated with the same criteria used for other research peptides: Batch-specific Certificate of Analysis, not a generic sample PDF HPLC purity and mass spectrometry identity confirmation Clear distinction between CJC-1295 no-DAC, CJC-1295 DAC, and blends No therapeutic claims, dosing claims, or implied human-use instructions Research-use-only labeling and purchase certification If a vendor describes CJC-1295/Ipamorelin as "FDA approved," "pharmaceutical grade," or an approved anti-aging therapy, that is a red flag. Frequently Asked Questions Is CJC-1295 Ipamorelin FDA approved? No. CJC-1295/Ipamorelin is not FDA approved as a combination product, and neither individual peptide has FDA approval for human therapeutic use. Is CJC-1295 FDA approved? No. FDA has evaluated CJC-1295-related bulk substances in the compounding context, but CJC-1295 is not a component of an FDA-approved drug. Is Ipamorelin FDA approved? No. Ipamorelin is not FDA approved. FDA has also listed Ipamorelin acetate with significant-risk concerns for compounding, including immunogenicity and limited safety information for some routes. Can compounding pharmacies make CJC-1295 Ipamorelin? Compounding eligibility is separate from FDA approval and depends on the specific substance, route, pharmacy type, state rules, and current FDA policy. Even when a compounded product exists, it is not FDA approved. What is the safest regulatory alternative? For an FDA-approved GHRH analog, tesamorelin is the closest comparison. It has an approved indication for HIV-associated lipodystrophy. CJC-1295/Ipamorelin does not share that status. Researchers comparing supply options can also review the Tesamorelin research peptide product page . References U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: CJC-1295-related bulk drug substances. fda.gov Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295. J Clin Endocrinol Metab . 2006;91(3):799-805. PubMed Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol . 1998;139(5):552-61. PubMed Disclaimer: This article is for informational and educational purposes only. CJC-1295 and Ipamorelin are not FDA-approved drugs. All research compounds referenced are intended for laboratory research only and are not for human consumption. PeptideStack does not provide medical advice. PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.